| 產(chǎn)品名稱 | Bexarotene - SR 11247 | Targretin |
| 產(chǎn)品貨號 | Axon 1700 CAS [153559-49-0] MF C24H28O2MW 348.48 Purity: 99% Soluble in DMSO Description Selective agonist for retinoid X receptors (RXR); An oral antineoplastic agent indicated for cutaneous T cell lymphoma (CTCL) References Certificates Categories Extra info R Gniadecki et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. Br. J. Dermatol. 2007, 157(3), 433–440. ? KH Dragnev et al. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer. Clin Cancer Res. 2007, 13(6), 1794-800. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology Retinoic Acid (RXR) NR2B Retinoid X Receptor antagonist Chemical name 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid Parent CAS No. [153559-49-0] Order Size Unit Price Stock 10 mg €65.00 In Stock |
| 產(chǎn)品價格 | 現(xiàn)貨詢價，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Bexarotene - SR 11247 | TargretinAxon 1700 CAS [153559-49-0] MF C24H28O2
Description
Selective agonist for retinoid X receptors (RXR); An oral antineoplastic agent indicated for cutaneous T cell lymphoma (CTCL)
Retinoid X Receptor antagonist
Chemical name4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoic acid Parent CAS No.[153559-49-0] |
| 產(chǎn)品資料 |
